A Study to Evaluate Whether Losartan Protects the Kidney in Hypertensive Diabetic Participants With Microalbuminuria (MK0954-365 AM1)

A Retrospective Survey to Evaluate the Renoprotective Effect of Losartan in Type II Diabetic Patients With Microalbuminuria and Hypertension in Real Life

This study will evaluate whether losartan protects the kidney in hypertensive Type II diabetic participants with microalbuminuria.

Inclusion Criteria:

• Diabetes mellitus
• Hypertension and has received losartan 50 mg or losartan 100 mg for at least 6 months
• Microalbuminuria (defined as microalbuminuria > 30 mg/g and < 300 mg/g by spot urine test)
• Serum creatinine ≤1.5 mg/dL for men and ≤1.4mg/dL for women
• Urinalysis with white blood cells (WBC) <5 cells per high power field
• Results of hemoglobin A1c (HbA1c), fasting blood glucose, serum creatinine, urine albumin/urine creatinine ratio and urinary analysis tests at baseline and 6 months after initiating the losartan therapy are available
• Medical history and co-morbidities (if available) listed in medical records
• Prescription information of antihypertensive regimen of losartan 50 mg or 100 mg available

Exclusion criteria:

• Treated with angiotensin-converting enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARB) before initiated treatment with losartan 50 mg or losartan 100 mg
• Enrollment in another clinical trial